Precision BioSciences Inc (DTIL)vsNovartis AG ADR (NVS)
DTIL
Precision BioSciences Inc
$6.26
+1.29%
HEALTHCARE · Cap: $171.68M
NVS
Novartis AG ADR
$145.71
-2.15%
HEALTHCARE · Cap: $271.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 125731% more annual revenue ($56.69B vs $45.05M). NVS leads profitability with a 22.5% profit margin vs -117.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
DTIL
Avoid33
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$13.23
Current Price
$6.26
$6.97 discount
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$145.71
$52.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.25 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 22.5% margins. DTIL offers better value entry with a 69.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?